If this agreement is intended to be used in conjunction with the "Eli Lilly and Company" (F-0794), half the class is working on the case, and the other half from the other. Lilly is considering buying Hybritech, but future flows of genetic engineering of money are difficult to predict and value. Both companies want to merge, but the cases that provide essentially the same information in all other respects, offer widely divergent projected cash flows. (Case B is F-0793). "Hide
by Robert F. Bruner, Casey Opitz C. Source: Darden School of Business 18 pages. Publication Date: March 28, 1991. Prod. #: UV2168-PDF-ENG
Related Case Solutions & Analyses:
Phon-Tech Corporation
Reynolds Metals Co.: Consumer Products Division
Jim Bender and Alert Inc. (A)
The Issue Process for Public Securities
Poland–1989 Supplement
Southwest Airlines–1993 (B)
Bitter Competition: The Holland Sweetener Co. vs. NutraSweet (D)
Beech-Nut Nutrition Corp. (D)
Fusion Systems Corp. in Japan (B)
Beech-Nut Nutrition Corp. (C): Conclusion
